Governance Revolution Medicines, Inc.

RVMD

US76155X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:40:17 13/03/2026 GMT			5-day change	1st Jan Change
96.24 ^USD	+1.23%		-1.98%	+21.09%

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Executive Committee: Revolution Medicines, Inc.

Manager

Positions heldSince

Mark Goldsmith

64 year

Chief Executive Officer	31/10/2014
Founder	30/09/2014
President	31/10/2014

Luan M. Wilfong

Human Resources Officer

04/03/2015

Wei Lin

64 year

Chief Tech/Sci/R&D Officer

31/03/2023

Jeff Cislini

51 year

General Counsel	31/08/2022
Corporate Secretary	31/08/2022

Wally Reiher

Chief Tech/Sci/R&D Officer

31/08/2020

Jack Anders

49 year

Director of Finance/CFO

30/09/2018

Steve Kelsey

65 year

Chief Tech/Sci/R&D Officer

28/02/2017

Peg Horn

63 year

Chief Operating Officer

30/09/2018

Composition of the Board of Directors: Revolution Medicines, Inc.

Director

CommitteesSince

Mark Goldsmith

64 year

Chairman

31/12/2019

Lorence Kim

52 year

Audit Committee Chair	04/09/2023
Governance Committee Chair
Nominating Committee Chair
Executive Committee	30/09/2022
Compensation Committee
Finance Committee Chair	30/09/2022
Audit Committee	30/09/2023

Elizabeth Anderson

68 year

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee	09/07/2019
Audit Committee	31/08/2022
Compensation Committee	31/08/2022

Alexis Borisy

54 year

Compensation Committee	03/05/2015
Governance Committee
Nominating Committee
Audit Committee	03/05/2015

Sandra Horning

77 year

Governance Committee	12/11/2020
Nominating Committee	12/11/2020

Franklin Clyburn

61 year

Compensation Committee	04/08/2024
Finance Committee

Thilo Schroeder

44 year

Audit Committee

28/02/2018

Sushil Patel

55 year

Audit Committee

15/06/2022

Flavia Borellini

64 year

Compensation Committee

Latest Appointments: Revolution Medicines, Inc.

01-08	PRESS DIGEST-Wall Street Journal - January 8	RE
29/09/25	Revolution Medicines, Inc. Announces Executive Appointments	CI
18/06/25	Revolution Medicines, Inc. Announces Resignation of Barbara Weber as Director, Member of the Board?S Nominating and Corporate Governance Committee and Member of the Board?S Research & Development Committee, Effective June 18, 2025	CI
16/09/24	89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer	MT
07/08/24	Revolution Medicines, Inc. Appoints Frank K. Clyburn, Jr. as Class II Director	CI
09/11/23	Revolution Medicines, Inc. Appoints Sandra J. Horning, M.D., as Member of the Board	CI
05/09/23	Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors	CI

More news

Former Officers and Directors: Revolution Medicines, Inc.

Insider

Positions held

SinceUntil

Barbara Weber

Director/Board Member	31/03/2018	17/06/2025
Independent Dir/Board Member	31/03/2018	17/06/2025

Daniel Simon

Corporate Officer/Principal

31/08/2022

31/12/2023

Eric Schmidt

Director/Board Member	16/06/2020	04/09/2023
Independent Dir/Board Member	16/06/2020	04/09/2023

Neil Exter

Director/Board Member	30/06/2019	11/07/2022
Independent Dir/Board Member	30/06/2019	11/07/2022

Vincent A. Miller

Director/Board Member	31/08/2017	15/06/2022
Independent Dir/Board Member	31/08/2017	15/06/2022

Peter Svennilson

Director/Board Member	16/06/2020	21/06/2021
Independent Dir/Board Member	16/06/2020	21/06/2021

Larry Lasky

Director/Board Member	19/12/2016	16/06/2020
Independent Dir/Board Member	19/12/2016	16/06/2020

Ryan Martins

Director of Finance/CFO

28/02/2018

30/09/2018

Michael Bonney

Director/Board Member

31/07/2016

31/08/2017

Abraham Bassan

Corporate Officer/Principal

30/11/2014

30/06/2017

Kevan Shokat

Founder

30/09/2014

17/12/2016

Michael Fischbach

Founder

30/09/2014

17/12/2016

Martin D Burke

Founder

30/09/2014

17/12/2016

Georgia Erbez

Director of Finance/CFO

30/04/2016

31/08/2016

David Pompliano

Chief Tech/Sci/R&D Officer	30/09/2014	-
Founder	30/09/2014	-

Elaine Heron

Director/Board Member

Carole A. Sable

Chief Tech/Sci/R&D Officer

04/03/2015

Age distribution of managers

Parity Men Women

Male	15
Female	4

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	8
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâ€™s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâ€™s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Employees

883

Sector

Biotechnology & Medical Research

More about the company